From: The Ripon Advance

U.S. House Energy and Commerce Committee Chairman Greg Walden (R-OR) and U.S. Senate Finance Committee Chairman Orrin Hatch (R-UT) have requested that the Office of Management and Budget (OMB) intensely review the economic impact of a proposed drug rebate rule before approving and publishing the rule.

OMB currently is reviewing the proposed Removal Of Safe Harbor Protection for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection rule, submitted jointly on July 18 by the U.S. Department of Health and Human Services (HHS) and the Office of the Inspector General (OIG). The proposed HHS/OIG rule would alter the use of rebates commonly used during negotiations between drug manufacturers and pharmacy benefit managers.

Read Complete Article